About: Survival of Patients {= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Background: The long-term efficacy and safety of alcohol septal ablation (ASA) has recently been demonstrated. However, there is still debate about the outcome of younger patients who should be treated using myectomy, according to American College of Cardiology Foundation/American Heart Association guidelines. The aim of this study was to evaluate the long-term outcome of patients {= 50 years of age after ASA for hypertrophic obstructive cardiomyopathy (HOCM). Methods: We retrospectively evaluated consecutive, highly symptomatic patients aged {= 50 years with HOCM who underwent ASA. Results: Institutional databases of 3 cardiovascular centres identified 290 patients with HOCM who underwent ASA; 75 (26%) of them were aged {= 50 years at the time of their first ASA. Median duration of follow-up was 5.1 years (range, 0.1-15.4 years). Four patients (5%) died during the study period (438 patient-years; the annual mortality rate was 0.91%; 95% confidence interval [CI], 0.25-2.34%; the annual mortality rate combined with the first appropriate implantable cardioverter-defibrillator discharge was 1.43%; 95% CI, 0.52-3.10%). Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 89-99%), 94% (95% CI, 84-98%), and 94% (95% CI, 84-98%), respectively. Conclusions: Results of this first study focused on HOCM patients aged {= 50 years who underwent ASA suggest a low risk of all-cause death or appropriate implantable cardioverter-defibrillator discharge in the long-term follow-up.
  • Background: The long-term efficacy and safety of alcohol septal ablation (ASA) has recently been demonstrated. However, there is still debate about the outcome of younger patients who should be treated using myectomy, according to American College of Cardiology Foundation/American Heart Association guidelines. The aim of this study was to evaluate the long-term outcome of patients {= 50 years of age after ASA for hypertrophic obstructive cardiomyopathy (HOCM). Methods: We retrospectively evaluated consecutive, highly symptomatic patients aged {= 50 years with HOCM who underwent ASA. Results: Institutional databases of 3 cardiovascular centres identified 290 patients with HOCM who underwent ASA; 75 (26%) of them were aged {= 50 years at the time of their first ASA. Median duration of follow-up was 5.1 years (range, 0.1-15.4 years). Four patients (5%) died during the study period (438 patient-years; the annual mortality rate was 0.91%; 95% confidence interval [CI], 0.25-2.34%; the annual mortality rate combined with the first appropriate implantable cardioverter-defibrillator discharge was 1.43%; 95% CI, 0.52-3.10%). Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 89-99%), 94% (95% CI, 84-98%), and 94% (95% CI, 84-98%), respectively. Conclusions: Results of this first study focused on HOCM patients aged {= 50 years who underwent ASA suggest a low risk of all-cause death or appropriate implantable cardioverter-defibrillator discharge in the long-term follow-up. (en)
Title
  • Survival of Patients {= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
  • Survival of Patients {= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy (en)
skos:prefLabel
  • Survival of Patients {= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
  • Survival of Patients {= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy (en)
skos:notation
  • RIV/00216208:11130/14:10292908!RIV15-MSM-11130___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, P(ED1.100/02/0123)
http://linked.open...iv/cisloPeriodika
  • 6
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 48716
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11130/14:10292908
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Alcohol Septal Ablation; Hypertrophic Obstructive Cardiomyopathy (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • CA - Kanada
http://linked.open...ontrolniKodProRIV
  • [AC97786FE0B4]
http://linked.open...i/riv/nazevZdroje
  • Canadian Journal of Cardiology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 30
http://linked.open...iv/tvurceVysledku
  • Tomašov, Pavol
  • Veselka, Josef
  • Zemánek, David
  • Branny, Marian
  • Januska, Jaroslav
  • Honek, Tomas
  • Krejci, Jan
  • Jahnlová, Denisa
http://linked.open...ain/vavai/riv/wos
  • 000339250300008
issn
  • 0828-282X
number of pages
http://bibframe.org/vocab/doi
  • 10.1016/j.cjca.2014.03.041
http://localhost/t...ganizacniJednotka
  • 11130
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software